Prague Med. Rep. 2021, 122, 243-256
Therapeutic Drug Monitoring of Protein Kinase Inhibitors in Breast Cancer Patients
Protein kinase inhibitors (PKIs) represent up-to-date therapeutic approach in breast cancer treatment. Although cancer is a rapidly progressive disease, many substances, including PKIs, are usually used at fixed doses without regard to each patient’s individuality. Therapeutic drug monitoring (TDM) is a tool that allows individualization of therapy based on drug plasma levels. For TDM conduct, exposure-response relationships of drug substances are required. The pharmacokinetic data and exposure-response evidence supporting the use of TDM for 6 PKIs used in breast cancer treatment, one of the most common female tumour diseases, are discussed in this review.
Keywords
Abemaciclib, Everolimus, Lapatinib, Neratinib, Palbociclib, Ribociclib.
Funding
This study was supported by the Charles University Project Progres Q25 and grant No. SVV 260 523.
References
Copyright
This is an open-access article distributed under the terms of the Creative Commons Attribution License.
